Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus
- PMID: 27261337
- DOI: 10.1136/gutjnl-2016-311715
Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus
Abstract
Objective: Since the publication of the Asia-Pacific consensus on gastro-oesophageal reflux disease in 2008, there has been further scientific advancement in this field. This updated consensus focuses on proton pump inhibitor-refractory reflux disease and Barrett's oesophagus.
Methods: A steering committee identified three areas to address: (1) burden of disease and diagnosis of reflux disease; (2) proton pump inhibitor-refractory reflux disease; (3) Barrett's oesophagus. Three working groups formulated draft statements with supporting evidence. Discussions were done via email before a final face-to-face discussion. We used a Delphi consensus process, with a 70% agreement threshold, using Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria to categorise the quality of evidence and strength of recommendations.
Results: A total of 32 statements were proposed and 31 were accepted by consensus. A rise in the prevalence rates of gastro-oesophageal reflux disease in Asia was noted, with the majority being non-erosive reflux disease. Overweight and obesity contributed to the rise. Proton pump inhibitor-refractory reflux disease was recognised to be common. A distinction was made between refractory symptoms and refractory reflux disease, with clarification of the roles of endoscopy and functional testing summarised in two algorithms. The definition of Barrett's oesophagus was revised such that a minimum length of 1 cm was required and the presence of intestinal metaplasia no longer necessary. We recommended the use of standardised endoscopic reporting and advocated endoscopic therapy for confirmed dysplasia and early cancer.
Conclusions: These guidelines standardise the management of patients with refractory gastro-oesophageal reflux disease and Barrett's oesophagus in the Asia-Pacific region.
Keywords: BARRETT'S OESOPHAGUS; GASTROESOPHAGEAL REFLUX DISEASE.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.Aliment Pharmacol Ther. 2004 Sep 15;20(6):637-43. doi: 10.1111/j.1365-2036.2004.02127.x. Aliment Pharmacol Ther. 2004. PMID: 15352912
-
Barrett's oesophagus: optimal strategies for prevention and treatment.Drugs. 2003;63(6):555-64. doi: 10.2165/00003495-200363060-00003. Drugs. 2003. PMID: 12656653 Review.
-
Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.Aliment Pharmacol Ther. 2008 Feb 15;27(4):321-6. doi: 10.1111/j.1365-2036.2007.03579.x. Epub 2007 Nov 28. Aliment Pharmacol Ther. 2008. PMID: 18047565
-
Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.Aliment Pharmacol Ther. 2021 May;53(9):968-976. doi: 10.1111/apt.16321. Epub 2021 Mar 11. Aliment Pharmacol Ther. 2021. PMID: 33705573
-
Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.Histopathology. 2005 Sep;47(3):268-75. doi: 10.1111/j.1365-2559.2005.02219.x. Histopathology. 2005. PMID: 16115227
Cited by
-
A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.J Neurogastroenterol Motil. 2021 Apr 30;27(2):165-175. doi: 10.5056/jnm20161. J Neurogastroenterol Motil. 2021. PMID: 33795539 Free PMC article.
-
Non-surgical animal model of gastroesophageal reflux disease by overeating induced in mice.J Investig Med. 2021 Aug;69(6):1208-1214. doi: 10.1136/jim-2020-001691. Epub 2021 Apr 16. J Investig Med. 2021. PMID: 33863754 Free PMC article.
-
The role of vonoprazan in patients with erosive esophagitis.Therap Adv Gastroenterol. 2022 Sep 13;15:17562848221122623. doi: 10.1177/17562848221122623. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36117573 Free PMC article. Review.
-
Concise Review: Applicability of High-resolution Manometry in Gastroesophageal Reflux Disease.J Neurogastroenterol Motil. 2022 Oct 30;28(4):531-539. doi: 10.5056/jnm22082. J Neurogastroenterol Motil. 2022. PMID: 36250360 Free PMC article. Review.
-
Irregular Z-Line: To Biopsy or Not to Biopsy?Dig Dis Sci. 2024 Aug;69(8):2734-2740. doi: 10.1007/s10620-024-08524-4. Epub 2024 Aug 1. Dig Dis Sci. 2024. PMID: 39090443 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical